ES2193414T3 - Dihidrobenzofuranos sustituidos como inhibidores de la pde. - Google Patents

Dihidrobenzofuranos sustituidos como inhibidores de la pde.

Info

Publication number
ES2193414T3
ES2193414T3 ES97950157T ES97950157T ES2193414T3 ES 2193414 T3 ES2193414 T3 ES 2193414T3 ES 97950157 T ES97950157 T ES 97950157T ES 97950157 T ES97950157 T ES 97950157T ES 2193414 T3 ES2193414 T3 ES 2193414T3
Authority
ES
Spain
Prior art keywords
pde
inhibitors
dihydrobenzofurans
substituted
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97950157T
Other languages
English (en)
Inventor
Hermann Amschler
Thomas Bar
Dieter Flockerzi
Beate Schmidt
Ulrich Thibaut
Armin Hatzelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Application granted granted Critical
Publication of ES2193414T3 publication Critical patent/ES2193414T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I), EN LA QUE R1 ES ALCOXI C 1-6 , CICLOALCOXI C 3-7 , CICLOALQUILMETOXI C 3-7 , BENCILOXI O ALCOXI C 1-4 PARCIAL O TOTALMENTE SUSTITUIDO POR FLUOR; R2 ES ALQUILO C 1-4 ; Y R3 ES HIDROGENO O ALQUILO C 1-4 ; O R2 Y R3, CONJUNTAMENTE E INCLUYENDO LOS DOS ATOMOS DE CARBONO A LOS QUE ESTAN UNIDOS, SON UN ANILLO HIDROCARBONADO DE 5, 6 O 7 MIEMBROS, DE ESTRUCTURA ESPIRO, SI SE DESEA INTERRUMPIDO POR UN ATOMO DE OXIGENO O POR UN GRUPO IMINO (- NH -); R4 ES HIDROGENO, HIDROXILO, NITRO, CIANO, CARBOXILO, ALCOXI C 1-4 O ALCOXICARBONILO C 1-4 ; A ES B, - CH(R5) - O > C = N - R6, DONDE B ES OXIGENO (- O -), IMINO (- NH -), SULFINILO (- S(O) ), SULFONILO (- S(O) SUB,2 -) O CARBONILIMINO (- C(O)NH -); Y R5 ES CARBOXILO, ALCOXICARBONILO C 1-4 , AMINOCARBONILO, MONO O DIALQUILAMINOCARB ONILO C 1-4 , HIDROXILAMINOCARBONILO (- C(O)NHOH), ALCOXIAMINOCARBONILO C 1-4 O UN RADICAL DE FORMULA (A), DONDE R51 ES HIDROGENO, ALQUILO C 1-4 O ARILO Y R52 ES HIDROGENO, ALQUILO C 1-4 O ARILO, DONDE ARILO ES UN RADICAL FENILO, PIRIDILO, BENCILO O FENETILO, QUE PUEDE NO ESTAR SUSTITUIDO O ESTAR MONO O DISUSTITUIDO POR HIDROXILO, ALCOXI C 1-4 , HALOGENO, AMINO, CIANO O NITRO; R6 ES HIDROXILO O ALQUILCARBONILOXI C 1-4 . DICHOS COMPUESTOS Y SUS SALES SON INHIBIDORES EFECTIVOS DE LA FOSFODIESTERASA (PDE).
ES97950157T 1996-11-20 1997-11-11 Dihidrobenzofuranos sustituidos como inhibidores de la pde. Expired - Lifetime ES2193414T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19647881 1996-11-20
EP96118743 1996-11-22

Publications (1)

Publication Number Publication Date
ES2193414T3 true ES2193414T3 (es) 2003-11-01

Family

ID=26031440

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97950157T Expired - Lifetime ES2193414T3 (es) 1996-11-20 1997-11-11 Dihidrobenzofuranos sustituidos como inhibidores de la pde.

Country Status (12)

Country Link
US (1) US6054475A (es)
EP (1) EP0941221B1 (es)
JP (1) JP2001505198A (es)
AT (1) ATE233252T1 (es)
AU (1) AU5320698A (es)
CY (1) CY2472B1 (es)
DE (1) DE69719358T2 (es)
DK (1) DK0941221T3 (es)
ES (1) ES2193414T3 (es)
PT (1) PT941221E (es)
SI (1) SI0941221T1 (es)
WO (1) WO1998022453A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021558A2 (en) * 1997-10-28 1999-05-06 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
EP1280523A2 (en) * 2000-05-03 2003-02-05 Sucampo AG Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
SE0004780D0 (sv) * 2000-12-22 2000-12-22 Jordanian Pharmaceutical Mfg & Novel compunds
JP3940290B2 (ja) * 2000-12-22 2007-07-04 ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド 新規化合物
ATE315555T1 (de) * 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
US7335680B2 (en) * 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279958B6 (sk) * 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
HU221504B (en) * 1994-07-22 2002-10-28 Byk Gulden Lomberg Chem Fab Dihydrobenzofuranes
US6080782A (en) * 1995-05-18 2000-06-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Cyclohexyl dihydrobenzofuranes
DK0828728T3 (da) * 1995-05-18 2003-05-19 Altana Pharma Ag Phenyldihydrobenzofuraner

Also Published As

Publication number Publication date
DE69719358T2 (de) 2003-12-24
US6054475A (en) 2000-04-25
AU5320698A (en) 1998-06-10
CY2472B1 (en) 2005-06-03
JP2001505198A (ja) 2001-04-17
WO1998022453A1 (en) 1998-05-28
DE69719358D1 (de) 2003-04-03
PT941221E (pt) 2003-07-31
SI0941221T1 (en) 2003-10-31
EP0941221B1 (en) 2003-02-26
EP0941221A1 (en) 1999-09-15
DK0941221T3 (da) 2003-06-10
ATE233252T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
ES2193414T3 (es) Dihidrobenzofuranos sustituidos como inhibidores de la pde.
ES2083595T3 (es) Derivados de indol que inhiben la biosintesis de leucotrienos.
DE69831937D1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
ATE234300T1 (de) Benzonaphthyridine als bronchialtherapeutika
DK0889886T3 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
CY2509B1 (en) New thiazole derivatives with phosphodiesterase-inhibitting effect
ES2188983T3 (es) Nuevas benzofuran-4-carboxamidas.
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
ATE219481T1 (de) 1,7,7-trimethyl-bicyclo(2.2.1)heptane derivative
PT1003724E (pt) Derivados substituidos com accao antiviral
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
MXPA03004023A (es) Compuestos quimicos.
PT100001A (pt) Novos derivados glicosilicos inibidores da gluco-hidrolase uteis como agentes antidiabeticos
PT914129E (pt) Utilizacao de aspirocloro ou derivados seus como agentes imunossupresivos
ECSP982785A (es) Nuevos compuestos de tetrahidroizoquinoleinil- carboxamida, de formula (i) y procedimiento para su obtencion